Pancreatic cancer is one of the most aggressive and lethal cancers worldwide. In 2008, 37680 estimated new cases were diagnosed in the United States, with a nearly identical rate of estimated deaths (34290) from pancreatic cancer. 1) Pancreatic cancer is highly resistant to chemotherapy and other forms of treatment.
2) Therefore, novel treatment modalities are worth being investigated.
In seeking novel anti-cancer drugs, matrine (dodecahydro3a,7a-diaza-benzo [de] anthracen-8-one, molecular formula: C 15 H 24 N 2 O), 3) an alkaloid extracted from a traditional Chinese herb, Sophora flavescens AIT., has drawn attention. Matrine has exhibited multiple pharmaceutical benefits, such as anti-inflammation, anti-virus and anti-fibrosis, in treating viral hepatitis and liver cirrhosis, [4] [5] [6] [7] and protected livers from ischemia reperfusion, without obvious toxicity or sideeffects. 7) Recently, matrine has displayed anti-tumor activities mainly by inhibiting the proliferation and/or inducing the apoptosis of cells from cervical cancer, leukemia, gastric cancer, hepatocellular carcinoma, lung cancer and breast cancer, [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] or induced the differentiation of leukemia K-562 cells. 12) Furthermore, matrine inhibits the adhesion and migration of cervical cancer HeLa cells, 13) the invasion and metastasis of human malignant melanoma A375 cells, 17) or the growth of established gastric tumors in mice. 11) We have previously reported that matrine inhibits the proliferation and induces the programmed cell death of rat glioma C6 cells in vitro. 16) The mechanisms accounting for its anti-cancer activities included regulating apoptosis-and proliferationrelated genes or proteins, such as N-ras, p53, c-myc, E2F-1, Apaf-1, Rb, Bcl-2 and caspases, [12] [13] [14] [15] [16] or regulating the transcriptional activity of eIF4E via dephosphorylation of 4E-BP1, 18) or vascular endothelial growth factor (VEGF)-Aktnuclear factor (NF)-kB signaling pathways. 19) However, little is known about its effects on pancreatic cancer. Therefore, the present study aims to investigate its anti-cancer activity and underlying mechanisms in human pancreatic cancer cells in vitro and subcutaneous xenograft tumors in mice in vivo.
MATERIALS AND METHODS

Mice, Cell Lines and Reagents
Male nude BALB/c mice, 6-8 weeks old, were obtained from the Animal Research Center, the First Affiliated Hospital of Harbin Medical University, China. The Human pancreatic cancer cell lines BxPC-3 and PANC-1 were obtained from the American Type Culture Collection (ATCC, Rockville, MD, U.S.A.). The normal human liver cell line, HL-7702, was obtained from the Cell Bank of Chinese Academy of Sciences. The cells were cultured in RPMI 1640 medium as described previously. 21) Matrine was purchased from Shaanxi Huike Botanical Development Co., Ltd., Xi'an, China (Batch No.: MA20070302, 98% purity). The antibodies against Bcl-2, Bax, Fas, cleaved caspase-8, cleaved caspase-9, cleaved caspase-3, PCNA (proliferating cell nuclear antigen) and b-actin were purchased from Santa Cruz Biotechnology, Santa Cruz, CA, U.S.A. The anti-Ki67 antibody (Ab) was purchased from Abcam.
3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium Bromide (MTT) Assay BxPC-3 (2ϫ10 3 ), PANC-1 (4ϫ10 3 ) and HL-7702 (4ϫ10 3 ) cells were seeded in 200 ml of RPMI 1640 medium into 96-well plates, and cultured overnight. Then the medium was replaced with fresh RPMI 1640 or the same media containing different concentrations of matrine (0.25-2.0 mg/ml). After a further incubation for 72 h, MTT (5 mg/ml, 20 ml) was added to each well, followed by a 4 h incubation. The medium was discarded and 150 ml of dimethyl sulfoxide (DMSO) was added into each well, and incubated for 20 min. The optical density (OD) 490 nm was measured. The cell viability index was calculated according to the formula: experimental OD value/control OD valueϫ100%. The experiments were repeated thrice.
In Vitro Cell Apoptosis Assay The cells were incubated with matrine as above for 72 h and harvested. 1ϫ10 5 cells were suspended in 100 ml binding buffer, the 5 ml of Annexin V and 5 ml of propidium iodide (PI) were added. The mixture was incubated for 15 min at room temperature in the dark, according to the manufacturer's instruction (BD Biosciences, San Jose, CA, U.S.A.). Then the cells were subjected to flow cytometry to measure the apoptosis rate (%) with a Beckman Coulter Epics Altra II cytometer (Beckman Coulter, California, U.S.A.). The experiments were repeated thrice.
Animal Experiments All surgical procedures and care administered to the animals were in accordance with institutional guidelines. Tumors were established by subcutaneous injection of 5ϫ10 6 BxPC-3 cells into the flanks of mice. Tumor volumes were estimated according to the formula: p/6ϫa 2 ϫb, where a is the short axis, and b the long axis. When tumors reached ca. 120 mm 3 at about 2 weeks, the mice were randomly assigned to 4 groups (each group had 7 mice): control and 3 treatment groups. The mice in the control group received a daily intraperitoneally (i.p.) injection of 100 ml of phosphate buffered saline (PBS), and the mice in the 3 treatment groups received i.p. injections of 100 ml matrine at doses of 50, 100 or 200 mg/kg, respectively. The mice were closely monitored, weighed, and euthanized 18 d after treatment, and the tumors harvested. Each tumor was split into two parts: one part was fixed with 10% buffered formalin, and the other part kept in a Ϫ80°C freezer for further analysis. The livers and kidneys were also removed and fixed with 10% buffered formalin, and histologically analyzed.
Terminal Deoxynucleotidyl Transferase Mediated Deoxyuridine Triphosphate (dUTP) Nick-End Labeling (TUNEL) Staining Tumor sections were stained with the TUNEL agent (Roche, Shanghai, China), and adjacent sections were counterstained with hematoxylin and eosin. The TUNEL positive cells were counted in 10 randomly selected ϫ400 high-power fields under fluorescence microscopy. The apoptosis index was calculated according to the following formula: the number of apoptotic cells/total number of nucleated cellsϫ100%.
Western Blotting Analysis The methodology has been described previously. 21) Briefly, cells were sonicated in radio-immunoprecipitation assay (RIPS) buffer and homogenized, or tumor tissues were homogenized in protein lysate buffer. Debris was removed by centrifugation, and the protein content was determined. Samples containing 30 mg total protein were resolved on polyacrylamide sodium dodecyl sulfate (SDS) gels, and electrophoretically transferred to polyvinylidene difluoride (PVDF) membranes. The membranes were blocked with 5% fat-free milk, incubated with primary antibodies, and subsequently with alkaline phosphatase-conjugated secondary antibody. They were developed with 5-bromo-4-chloro-3-indolyl phosphate/nitro blue tetrazolium (Tiangen Biotech Co., Ltd., Beijing, China). Blots were stained with anti-b-actin Ab to confirm that each lane contained similar amounts of tumor homogenate.
Ki-67 Proliferation Index The methodology has been described previously. 21) Briefly, Tumor sections were blocked with 3% bovine serum albumin (BSA), and then incubated with an anti-Ki-67 Ab. They were subsequently incubated for 30 min with the secondary Ab using the Ultra Sensitive TMS-P kit (Zhongshan Co., Beijing, China), and immunoreactivity was developed with Sigma FAST 3,3Ј-diaminobenzidine tetrahydrochloride (DAB) and CoCl 2 enhancer tablets (Sigma-Aldrich, Shanghai, China). Sections were counterstained with hematoxylin. The Ki-67 positive cells were counted in 10 randomly selected ϫ400 high-power fields under microscopy. The Ki-67 proliferation index was calculated according to the following formula: the number of Ki-67 positive cells/the total cell countϫ100%.
Statistical Analysis The results were expressed as mean valuesϮstandard deviation (S.D.), and an analysis of variance (ANOVA) and Dunnett t test were used to evaluate statistical significance. A value of less than 0.05 (pϽ0.05) was used for statistical significance.
RESULTS
Matrine Inhibits the Growth of Pancreatic Cancer Cells but Not Normal Liver Cells in Vitro
As shown in Fig. 1 , matrine reduced the viability of two types of pancreatic cancer cells in a dose-dependent manner. With a logarithmic regression analysis, the concentration of matrine which resulted in 50% of maximal proliferation inhibition (IC 50 ) of cells was calculated. The IC 50 value was 0.73 mg/ml for BxPC-3 cells, and 0.91 mg/ml for PANC-1 cells. However, matrine had no significant effect on the viability of normal HL-7702 cells. We also detected the expression levels of PCNA with Western blot analysis, which showed that matrine downregulated the expression of PCNA in a dose-dependent manner, in both BxPC-3 and PANC-1 cells (Fig. 1B) .
Matrine Induces Apoptosis of Pancreatic Cancer Cells in Vitro BxPC-3 and PANC-1 cells were incubated with matrine at different concentrations for 72 h, and flow cytometric analysis was used to measure the apoptosis rates. As shown in Fig. 2A , matrine increased the apoptosis rate in a dose-dependent manner. Matrine at a concentration of 0.25 mg/ml led to an apoptosis rate of BxPC-3 cells at 9.90Ϯ2.82%, which was significantly higher than that of the untreated cells (pϽ0.05). Furthermore, 0.75 or 1.25 mg/ml of matrine resulted in a highly significantly higher apoptosis rates (33.67Ϯ5.42% or 48.83Ϯ3.91%, respectively) than the controls (pϽ0.001). Similarly, matrine also increased the apoptosis rates of PANC-1 cells in a dose-dependent manner (Fig. 2A) . The representative histograms of flow cytometry showed the apoptosis rates of BxPC-3 cells of 2.81%, 11.29%, 34.60% or 50.47% when they were treated with matrine at concentrations of 0, 0.25, 0.75 and 1.25 mg/ml, respectively (Fig. 2B upper panel) , while that of PANC-1 cells were 4.13%, 8.71%, 24.56% and 42.55% (Fig. 2B lower  panel) .
We further examined the expression of apoptosis-related proteins in the two types of cells with Western blot analysis. Matrine treatment upregulated the expression of Bax and downregulated the expression of Bcl-2 (thus reducing the ratio of Bcl-2/Bax), upregulated the expression of Fas, and increased the activation of caspases-8, -9 and -3, in the two types of cells in a dose-dependent manner (Fig. 2C , BxPC-3 cells; Fig. 2D, PANC-1 cells) .
Administration of Matrine Inhibits Pancreatic Tumors in Vivo without Significant Side-Effects BxPC-3 tumors were established in mice. When the tumors reached around 120 mm 3 , the mice were randomly assigned to four groups to receive daily injection of PBS (control), or 50, 100, or 200 mg/kg of matrine, respectively. As shown in Fig. 3A , tumors in the control group grew remarkably fast, reaching 984.23Ϯ 124.54 mm 3 in volume 18 d after injection. Administration of matrine at a dose of 50 mg/kg resulted in a reduction of tumor volume (778.63Ϯ89.51 mm 3 ) compared to the control, but the difference did not reach significance. In contrast, the tumors of mice treated with 100 mg/kg or 200 mg/kg of matrine were significantly (pϽ0.01) smaller than control tumors, reaching only 489.24Ϯ72.17, and 304.81Ϯ48.34 mm 3 in volume, respectively, 18 d after treatment. As shown in Fig. 3B , the bodyweight of matrine-treated mice did not significantly differ from the control mice. The histological analysis of livers and kidneys from both the control and matrine-treated mice did not reveal obvious pathological alterations (data not shown).
Matrine Regulates Expression of PCNA and Apoptosis- 
Related Proteins in Situ
We further detected tumoral expression of PCNA and apoptosis-related proteins, and found that matrine therapy downregulated the expression of PCNA and Bcl-2, and upregulated the expression of Bax and Fas, thus reducing the ratio of Bcl-2/Bax, and also increased the activation of caspase-9,-8 and -3, in a dose-dependent manner, in accordance with the findings in vitro (Fig. 3B) .
Matrine Inhibits Cell Proliferation in Situ Tumor sections from above were stained with an Ab against Ki-67, a cell proliferation marker. As shown in the representative photographs, compared to the control group (Fig. 4A) , there were slightly fewer Ki-67 positive cells in tumors in the 50 mg/kg matrine group (Fig. 4B) , and obviously fewer Ki-67 positive cells in the 100 (Fig. 4C) or 200 (Fig. 4D ) mg/kg matrine groups. Ki-67 positive cells in sections were counted to record the Ki-67 proliferation index. As shown in Fig. 4E , the inhibitory effects of matrine on the proliferation index acted in a dose-dependent manner. Matrine therapy at the dose of 50 mg/kg resulted in a slight reduction in the proliferation index compared with the control, but the difference did not reach significance. Matrine therapy at the dose of 100 mg/kg reduced the proliferation index by 35% (pϽ0.05), and at the dose of 200 mg/kg, by 49% (pϽ0.001), compared with the control (Fig. 4E) .
Matrine Induces Cell Apoptosis in Situ
Tumor sections from above were stained with the TUNEL agent to examine apoptotic cells. A small number of apoptotic cells were detected in tumors in the control group (Fig. 5A) , whereas a greater number of apoptotic cells were detected in tumors in all three matrine treatment groups at doses of 50 (Fig. 5B), 100 (Fig. 5C), or 200 (Fig. 5D ) mg/kg. The apoptotic cells in sections were counted to record the apoptosis index. As shown in Fig. 5E , the effects of matrine on the apoptosis index were at dose-dependent. Matrine therapy at the dose of 50 mg/kg resulted in an apoptosis index of 10.29Ϯ2.06%, which is significantly (pϽ0.05) higher than that in the control group (4.43Ϯ0.85%). Furthermore, matrine treatments at doses of 100 and 200 mg/kg led to apoptosis indexes of 19.8Ϯ4.16% and 24.17Ϯ4.90%, respectively, which were highly significantly (pϽ0.001) higher than that in the control group (Fig. 5E ).
DISCUSSION
The present study has demonstrated that matrine exhibited therapeutic effects against human pancreatic cancer cells in vitro and subcutaneous xenograft tumors in mice. Its antiproliferative activity may rely on the downregulation of PCNA expression, and pro-apoptotic activity, reduction of the ratio of Bcl-2/Bax, upregulation of Fas expression, and increased activation of caspase-8, caspase-9 and caspase-3. Since the discovery of matrine as a potential anti-cancer drug, many lines of studies have examined the therapeutic effects of matrine including inhibiting cell proliferation, and inducing cellular differentiation and apoptosis, in various types of cancer cells, [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] however, to our knowledge, the effect of matrine on pancreatic cancer has not been reported previously; and most of those studies examined its anti-tumor activity in cultured cancer cells.
Uncontrolled proliferation is one of the major biological features of cancer cells, and inhibiting cell proliferation could achieve the arrest of tumor growth. The present study has shown that matrine inhibited the proliferation of pancreatic cancer cells in vitro and in vivo. PCNA is a 36 kDa, highly conserved nuclear protein required for DNA synthesis via DNA polymerases d and e. PCNA is also required for post-replicative DNA repair through interactions with MSH2 and MLH1. 22, 23) By downregulating PCNA expression, matrine could inhibit DNA synthesis and repair, thus inhibiting cell proliferation.
Cellular apoptosis can be triggered by the death receptor extrinsic pathway and/or the mitochondrial intrinsic pathway. 24) In the mitochondrial pathway, the released cytochrome c from mitochondria binds to Apaf-1, resulting in proteolytic processing and activation of caspase-9, initiating a cascade of additional caspase activation that culminates in apoptosis. 25) The members of the Bcl-2 family are the most prominent regulators of apoptosis. 26) Bcl-2, located on the membrane of mitochondria, is an anti-apoptotic protein, while Bax is a pro-apoptotic one by inhibiting the function of Bcl-2.
27) Matrine has been shown to induce the apoptosis of gastric cancer MKN45 cells via increasing pro-apoptotic molecules of the Bcl-2 family. 14) Matrine triggers the apoptosis of leukemia K562 cells primarily through the mitochondrial pathway, including upregulation of Apaf-1, Bax translocation, cytochrome c release and activation of caspase-9 and -3. 28, 29) The regulation of Bcl-2/Bax expression and caspase-3 activation has also been observed in matrine-induced apoptosis of angiotensin II-stimulated hyperplasia of cardiac fibroblasts, 3) breast cancer cells, 19) and human lung cancer and hepatoma cells. 20) The present study has demonstrated that matrine-induced apoptosis was accompanied by a decrease in Bcl-2 and a concomitant increase in Bax in pancreatic cancer cells, and increased the activation of caspase-9 and -3 in a dose-dependent manner, indicating that mitochondrial pathway may be involved in matrine-induced apoptosis of pancreatic cancer cells. We have previously reported that matrine induced apoptosis by upregulating Bcl-2 at mRNA levels in a cDNA-microarray. 15) We propose that matrine regulates the expression of Bcl-2 and Bax, leading to the release of cytochrome c from the mitochondria to trigger the activation of downstream initiator caspase-9, resulting in activation of the effector caspases. In addition, matrine has been shown to induce the apoptosis of gastric cancer SGC-7901 cells via the alteration of Fas/FasL and activation of caspase-3, indicating the death receptor pathway may also be involved in matrineinduced apoptosis. 30) In our previous report, matrine upregulated the expression of 14 members of TNF gene family in a PCR array in glioma cells, implying that the death receptor pathway might be involved in matrine-induced cell apoptosis. 15) In accord, the present study has shown that matrine upregulated the expression of Fas and increased the activation of caspase-8 in pancreatic cancer cells, suggesting the death receptor pathway may also be involved in matrineinduced apoptosis in pancreatic cancer cells. However, further investigation is required to examine whether matrine regulates the expression of other molecules involved in the death receptor pathway.
To summarize, the present study, to our knowledge, is the first one to investigate the anti-cancer effects of matrine and the underlying mechanisms in pancreatic cancer cells in vitro and in vivo. Compared to conventional chemotherapeutic agents, matrine, of natural resource, is of less cost, and exhibits no serious adverse cytotoxicity. 8) All these features have made matrine a potential and attractive anti-cancer agent in treating pancreatic cancer. Furthermore, matrine has displayed synergistic effects with a chemotherapeutic drug, 5-fluorouracil, in treating implanted human gastric tumors in mice, 11) and also with other agents including celecoxib, trichostatin and rosiglitazone in inhibiting the proliferation of human breast cancer cells. 19) These studies imply that matrine might have synergistic effects with gemcitabine, a current first-line treatment for pancreatic cancer, 31) though further investigation is required.
